Year archive

IRLAB Therapeutics — 2023 filings

All 36 regulatory filings released by IRLAB Therapeutics (IRLAB) in 2023, sourced directly from the official regulator.

36 Filings

2023 Period

2023 filings (36)

Filing	Released	Lang
IRLAB förlänger VD:s förordnande Board/Management Information	2023-12-27	Swedish
IRLAB extends CEO appointment Board/Management Information	2023-12-27	English
IRLAB increases its liquidity with a loan facility of up to SEK 55 million that extends financial runway and increases business opportunities Capital/Financing Update	2023-12-22	English
IRLAB förstärker likviditeten med en lånefacilitet om upp till 55 MSEK som förlänger bolagets finansiella runway och ökar affärsmöjligheterna Capital/Financing Update	2023-12-22	Swedish
IRLAB receives grant from The Michael J. Fox Foundation to support development of IRL757 for the treatment of apathy Regulatory Filings	2023-12-21	English
IRLAB får finansiering från The Michael J. Fox Foundation för utveckling av IRL757 för behandling av apati Regulatory Filings	2023-12-21	Swedish
Valberedningen utsedd inför IRLAB:s årsstämma 2024 Board/Management Information	2023-11-07	Swedish
Nomination committee appointed for IRLAB’s annual general meeting 2024 Board/Management Information	2023-11-07	English
Interim / Quarterly Report 2023 Interim / Quarterly Report 9M 2023	2023-10-25	Swedish
Interim / Quarterly Report 2023 Interim / Quarterly Report 9M 2023	2023-10-25	English
Interim / Quarterly Report 2023 Interim / Quarterly Report H1 2023	2023-08-30	Swedish
Interim / Quarterly Report 2023 Interim / Quarterly Report H1 2023	2023-08-30	English
IRLAB secures full ownership of the mesdopetam project and continues product development Regulatory Filings	2023-08-21	English
IRLAB säkrar äganderätten till mesdopetamprojektet och fortsätter produktutvecklingen Regulatory Filings	2023-08-21	Swedish
Kommuniké från årsstämma i IRLAB Therapeutics AB AGM Information	2023-06-20	Swedish
Report from the Annual General meeting of IRLAB Therapeutics AB AGM Information	2023-06-20	English
Kallelse till årsstämma i IRLAB Therapeutics AB AGM Information	2023-05-19	Swedish
IRLAB och McQuade Center for Strategic Research and Development ingår avtal för utvärdering av IRLAB:s neuropsykiatriska program IRL757 och IRL942 Report Publication Announcement	2023-05-16	Swedish
IRLAB Therapeutics and the McQuade Center for Strategic Research and Development Enter into Agreement to Evaluate IRLAB’s Neuropsychiatric Programs IRL757 and IRL942 Regulatory Filings	2023-05-16	English
Interim / Quarterly Report 2023 Interim / Quarterly Report Q1 2023	2023-05-10	Swedish
Interim / Quarterly Report 2023 Interim / Quarterly Report Q1 2023	2023-05-10	English
IRLAB kommenterar uppgifter i Ipsens Universella registreringsdokument 2022 och mesdopetams fortsatta utveckling Regulatory Filings	2023-05-03	Swedish
IRLAB comments on statements in Ipsen’s 2022 Universal Registration Document and the further development of mesdopetam Regulatory Filings	2023-05-03	English
Annual Report 2022 Annual Report FY 2022	2023-04-28	Swedish
Annual Report 2022 Annual Report FY 2022	2023-04-28	Swedish
IRLAB meddelar nytt datum för publicering av årsredovisning Report Publication Announcement	2023-04-20	Swedish
IRLAB announces new date for publication of the annual report Report Publication Announcement	2023-04-20	English
Director's Dealing 2023 Director's Dealing	2023-03-07	English
Interim / Quarterly Report 2022 Interim / Quarterly Report FY 2022	2023-02-23	Swedish
Interim / Quarterly Report 2022 Interim / Quarterly Report Q4 2022	2023-02-23	English
IRLAB meddelar att styrelseledamot lämnar bolagets styrelse Board/Management Information	2023-02-21	Swedish
IRLAB reports that board member leaves the company’s Board Board/Management Information	2023-02-21	English
IRLAB byter vd och utser ny styrelseordförande Board/Management Information	2023-02-20	Swedish
IRLAB changes CEO and appoints new Chairman Board/Management Information	2023-02-20	English
IRLAB announces top-line results from Phase IIb trial of mesdopetam (IRL790) in Parkinson’s disease Earnings Release FY 2023	2023-01-17	English
IRLAB rapporterar top-line resultat från Fas IIb-studien med mesdopetam (IRL790) i Parkinsons sjukdom Earnings Release FY 2023	2023-01-17	Swedish